– CANADA, Winnipeg – Kane Biotech Inc. (TSX-V:KNE / OTCQB:KNBIF), is pleased to announce it has appointed Rashieda (Rivka) Gluck to the Corporation’s Board of Directors. With over 20 years of experience in the global pharmaceutical, biotechnology, and life science industries, Ms. Gluck’s career has spanned all levels and functions in clinical development.  As an executive, her focus has been on leading the strategic planning and successful implementation of high quality clinical development programs.

Ms. Gluck’s leadership in the life sciences industry spans both publicly-traded and private companies. Currently, Ms. Gluck is on the executive management team of Aurinia Pharmaceuticals, developing and implementing their overall corporate strategy. She also leads all clinical operations for their lead drug, voclosporin. Prior to that, Ms. Gluck has held management-level, clinical operations roles at innovative companies including Qu Biologics, Vifor Pharma, Novartis, and GlaxoSmithKline, among others.

Mark Ahrens-Townsend, President & CEO of Kane Biotech, commented, “We are proud to appoint Rashieda to our Board of Directors, bringing her wealth of experience in overseeing and effectively running clinical operations in many environments. She is ideally suited to help guide Kane Biotech at this time with the number of clinical and efficacy studies we currently have ongoing for multiple pet and human health-related conditions. Her clinical development knowledge, as well as her ability to run efficient programs and her versatility in multiple aspects of healthcare and life sciences, is a solid strategic match for the broad applicability of our biofilm-preventing technologies.”

Ms. Gluck currently serves as Senior Vice President of Global Clinical Operations at Aurinia Pharmaceuticals Inc. since February 2018 and has also served as its Vice President of Clinical Operations since January 1, 2016. She previously served as Vice President of Clinical Operations at Qu Biologics Inc. and was responsible for leading their clinical programs and providing strategic direction for the clinical development of their platform immunotherapeutic treatments in multiple disease indications. Prior to that, Ms. Gluck served as Vice President of Clinical Operations at Aspreva in New Jersey and was responsible for the successful integration of the global clinical operations department post acquisition by Zurich-based Vifor Pharmaceuticals. At Vifor, she served as Vice President and Head of Global Clinical Operations where she was a member of the Research, Development, and Leadership team and continued to build and lead the clinical research department in Zurich and hold overall accountability for the execution and delivery of all global clinical programs. In her career, Ms. Gluck served in increasingly senior positions at major pharmaceutical companies including Novartis, Organon, and GSK. Ms. Gluck holds a B.Sc. in Nursing from the University of British Columbia.

About Kane Biotech

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

The Corporation has a portfolio of biotechnologies, intellectual property (75 patents and patents pending, trade secrets and trademarks) and products developed by the Corporation’s own biofilm research expertise and acquired from leading research institutions. StrixNB, DispersinB, Aledex, bluestem, AloSera, coactiv+ and Kane are trademarks of Kane Biotech Inc.   The Corporation is listed on the TSX Venture Exchange under the symbol “KNE” and on the OTCQB Venture Market under the symbol “KNBIF”.

For more information : http://www.kanebiotech.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>

Comments are closed.